|
Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. |
|
|
Consulting or Advisory Role - Eisai (Inst); Pfizer (Inst); Roche (Inst) |
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst) |
|
|
Travel, Accommodations, Expenses - Merck |
|
|
No Relationships to Disclose |
|
|
Honoraria - Eisai; Genzyme |
Speakers' Bureau - Eisai; Genzyme |
Research Funding - AstraZeneca; Genzyme |
Travel, Accommodations, Expenses - Celgene; Genzyme; Imaging Equipment Limited; Ipsen |
|
|
Speakers' Bureau - Merck Serono; Merck Serono; Merck Serono |
Research Funding - Gilead Sciences (Inst) |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Amgen (Inst) |